The initial treatment of Parkinson's disease should begin with levodopa
Identifieur interne : 004C24 ( Main/Exploration ); précédent : 004C23; suivant : 004C25The initial treatment of Parkinson's disease should begin with levodopa
Auteurs : William J. Weiner [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1999-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Benzothiazoles, Bromocriptine (therapeutic use), Chemotherapy, Dopamine receptor agonists, Drug Therapy, Combination, Early, Essential Tremor (drug therapy), Female, Human, Humans, Indoles (therapeutic use), Levodopa, Levodopa (pharmacology), Levodopa (therapeutic use), Levodopa‐sparing strategies, Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Pergolide (therapeutic use), Receptors, Dopamine (drug effects), Thiazoles (therapeutic use), Time Factors, Toxicity, Treatment.
- MESH :
- chemical , drug effects : Receptors, Dopamine.
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Bromocriptine, Indoles, Levodopa, Pergolide, Thiazoles.
- drug therapy : Essential Tremor, Parkinson Disease.
- Aged, Benzothiazoles, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Time Factors.
Abstract
For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopamine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long‐term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa‐sparing strategies and levodopa‐induced toxicity in Parkinson's disease. At this time, there is little evidence to support levodopa‐sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.
Url:
DOI: 10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001686
- to stream Istex, to step Curation: 001686
- to stream Istex, to step Checkpoint: 003390
- to stream Main, to step Merge: 007922
- to stream PascalFrancis, to step Corpus: 002D67
- to stream PascalFrancis, to step Curation: 003A57
- to stream PascalFrancis, to step Checkpoint: 002D04
- to stream Main, to step Merge: 007B53
- to stream PubMed, to step Corpus: 004138
- to stream PubMed, to step Curation: 004138
- to stream PubMed, to step Checkpoint: 004087
- to stream Ncbi, to step Merge: 000113
- to stream Ncbi, to step Curation: 000113
- to stream Ncbi, to step Checkpoint: 000113
- to stream Main, to step Merge: 007694
- to stream Main, to step Curation: 004C24
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa</title><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:42D0059395A046E21B2586D694C8D0DB5F953E86</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q</idno><idno type="url">https://api.istex.fr/document/42D0059395A046E21B2586D694C8D0DB5F953E86/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001686</idno><idno type="wicri:Area/Istex/Curation">001686</idno><idno type="wicri:Area/Istex/Checkpoint">003390</idno><idno type="wicri:doubleKey">0885-3185:1999:Weiner W:the:initial:treatment</idno><idno type="wicri:Area/Main/Merge">007922</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:99-0475653</idno><idno type="wicri:Area/PascalFrancis/Corpus">002D67</idno><idno type="wicri:Area/PascalFrancis/Curation">003A57</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002D04</idno><idno type="wicri:doubleKey">0885-3185:1999:Weiner W:the:initial:treatment</idno><idno type="wicri:Area/Main/Merge">007B53</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:10495031</idno><idno type="wicri:Area/PubMed/Corpus">004138</idno><idno type="wicri:Area/PubMed/Curation">004138</idno><idno type="wicri:Area/PubMed/Checkpoint">004087</idno><idno type="wicri:Area/Ncbi/Merge">000113</idno><idno type="wicri:Area/Ncbi/Curation">000113</idno><idno type="wicri:Area/Ncbi/Checkpoint">000113</idno><idno type="wicri:doubleKey">0885-3185:1999:Weiner W:the:initial:treatment</idno><idno type="wicri:Area/Main/Merge">007694</idno><idno type="wicri:Area/Main/Curation">004C24</idno><idno type="wicri:Area/Main/Exploration">004C24</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The initial treatment of Parkinson's disease should begin with levodopa</title><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Miami School of Medicine, Miami, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-09">1999-09</date><biblScope unit="vol">14</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="716">716</biblScope><biblScope unit="page" to="724">724</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">42D0059395A046E21B2586D694C8D0DB5F953E86</idno><idno type="DOI">10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q</idno><idno type="ArticleID">MDS1002</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (pharmacology)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antiparkinson agent</term><term>Benzothiazoles</term><term>Bromocriptine (therapeutic use)</term><term>Chemotherapy</term><term>Dopamine receptor agonists</term><term>Drug Therapy, Combination</term><term>Early</term><term>Essential Tremor (drug therapy)</term><term>Female</term><term>Human</term><term>Humans</term><term>Indoles (therapeutic use)</term><term>Levodopa</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Levodopa‐sparing strategies</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Pergolide (therapeutic use)</term><term>Receptors, Dopamine (drug effects)</term><term>Thiazoles (therapeutic use)</term><term>Time Factors</term><term>Toxicity</term><term>Treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Bromocriptine</term><term>Indoles</term><term>Levodopa</term><term>Pergolide</term><term>Thiazoles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Essential Tremor</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Benzothiazoles</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Homme</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Précoce</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopamine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long‐term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa‐sparing strategies and levodopa‐induced toxicity in Parkinson's disease. At this time, there is little evidence to support levodopa‐sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li></region></list><tree><country name="États-Unis"><region name="Floride"><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004C24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:42D0059395A046E21B2586D694C8D0DB5F953E86
|texte= The initial treatment of Parkinson's disease should begin with levodopa
}}
| This area was generated with Dilib version V0.6.23. |  |